BIOMERICA INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BIOMERICA INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $5.31M | Aug 29, 2025 |
| FY2025 | May 31, 2024 | $5.42M | Aug 29, 2025 |
| FY2024 | May 31, 2023 | $5.34M | Aug 28, 2024 |
| FY2023 | May 31, 2022 | $18.87M | Aug 25, 2023 |
| FY2022 | May 31, 2021 | $7.20M | Aug 29, 2022 |
| FY2021 | May 31, 2020 | $6.69M | Oct 14, 2021 |
| FY2020 | May 31, 2019 | $5.20M | Aug 31, 2020 |
| FY2019 | May 31, 2018 | $5.56M | Aug 29, 2019 |
| FY2018 | May 31, 2017 | $5.79M | Aug 29, 2018 |
| FY2012 | May 31, 2012 | $6.08M | Aug 29, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $5.31M | Aug 29, 2025 |
| FY2025 | May 31, 2024 | $5.42M | Aug 29, 2025 |
| FY2024 | May 31, 2023 | $5.34M | Aug 28, 2024 |
| FY2023 | May 31, 2022 | $18.87M | Aug 25, 2023 |
| FY2022 | May 31, 2021 | $7.20M | Aug 29, 2022 |
| FY2021 | May 31, 2020 | $6.69M | Oct 14, 2021 |
| FY2020 | May 31, 2019 | $5.20M | Aug 31, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | May 31, 2017 | $5.79M | Aug 29, 2017 |
| FY2017 | May 31, 2016 | $5.14M | Aug 29, 2017 |
| FY2016 | May 31, 2015 | $4.96M | Aug 29, 2016 |
| FY2015 | May 31, 2014 | $5.12M | Aug 31, 2015 |
| FY2014 | May 31, 2013 | $6.47M | Aug 29, 2014 |
| FY2013 | May 31, 2012 | $6.08M | Aug 29, 2013 |
| FY2012 | May 31, 2011 | $4.90M | Aug 29, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $498.0K | Aug 29, 2025 |
| FY2025 | May 31, 2024 | $611.0K | Aug 29, 2025 |
| FY2024 | May 31, 2023 | $446.0K | Aug 28, 2024 |
| FY2023 | May 31, 2022 | $2.98M | Aug 25, 2023 |
| FY2022 | May 31, 2021 | $366.3K | Aug 29, 2022 |
| FY2021 | May 31, 2020 | $1.74M | Oct 14, 2021 |
| FY2020 | May 31, 2019 | $1.29M | Aug 31, 2020 |
| FY2019 | May 31, 2018 | $1.75M | Aug 29, 2019 |
| FY2018 | May 31, 2017 | $2.02M | Aug 29, 2018 |
| FY2017 | May 31, 2016 | $1.52M | Aug 29, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($4.97M) | Aug 29, 2025 |
| FY2025 | May 31, 2024 | ($5.98M) | Aug 29, 2025 |
| FY2024 | May 31, 2023 | ($7.14M) | Aug 28, 2024 |
| FY2023 | May 31, 2022 | ($4.53M) | Aug 25, 2023 |
| FY2022 | May 31, 2021 | ($7.45M) | Aug 29, 2022 |
| FY2021 | May 31, 2020 | ($2.68M) | Oct 14, 2021 |
| FY2020 | May 31, 2019 | ($2.39M) | Aug 31, 2020 |
| FY2019 | May 31, 2018 | ($1.47M) | Aug 29, 2019 |
| FY2018 | May 31, 2017 | ($908.6K) | Aug 29, 2018 |
| FY2017 | May 31, 2016 | ($1.50M) | Aug 29, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($5.14M) | Aug 29, 2025 |
| FY2025 | May 31, 2024 | ($6.37M) | Aug 29, 2025 |
| FY2024 | May 31, 2023 | ($7.22M) | Aug 28, 2024 |
| FY2023 | May 31, 2022 | ($4.53M) | Aug 25, 2023 |
| FY2022 | May 31, 2021 | ($7.50M) | Aug 29, 2022 |
| FY2021 | May 31, 2020 | ($2.74M) | Oct 14, 2021 |
| FY2020 | May 31, 2019 | ($2.41M) | Aug 31, 2020 |
| FY2019 | May 31, 2018 | ($1.48M) | Aug 29, 2019 |
| FY2018 | May 31, 2017 | ($954.6K) | Aug 29, 2018 |
| FY2017 | May 31, 2016 | ($827.0K) | Aug 29, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $1.02M | Aug 29, 2025 |
| FY2025 | May 31, 2024 | $1.49M | Aug 29, 2025 |
| FY2024 | May 31, 2023 | $1.58M | Aug 28, 2024 |
| FY2023 | May 31, 2022 | $1.81M | Aug 25, 2023 |
| FY2022 | May 31, 2021 | $2.19M | Aug 29, 2022 |
| FY2021 | May 31, 2020 | $1.93M | Oct 14, 2021 |
| FY2020 | May 31, 2019 | $1.68M | Aug 31, 2020 |
| FY2019 | May 31, 2018 | $1.40M | Aug 29, 2019 |
| FY2018 | May 31, 2017 | $1.13M | Aug 29, 2018 |
| FY2017 | May 31, 2016 | $780.3K | Aug 29, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $4.61M | Aug 29, 2025 |
| FY2025 | May 31, 2024 | $5.49M | Aug 29, 2025 |
| FY2024 | May 31, 2023 | $6.09M | Aug 28, 2024 |
| FY2023 | May 31, 2022 | $5.70M | Aug 25, 2023 |
| FY2022 | May 31, 2021 | $5.67M | Aug 29, 2022 |
| FY2021 | May 31, 2020 | $2.55M | Oct 14, 2021 |
| FY2020 | May 31, 2019 | $2.03M | Aug 31, 2020 |
| FY2019 | May 31, 2018 | $1.84M | Aug 29, 2019 |
| FY2018 | May 31, 2017 | $1.85M | Aug 29, 2018 |
| FY2017 | May 31, 2016 | $1.57M | Aug 29, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($3.84M) | Aug 29, 2025 |
| FY2025 | May 31, 2024 | ($5.36M) | Aug 29, 2025 |
| FY2024 | May 31, 2023 | ($5.47M) | Aug 28, 2024 |
| FY2023 | May 31, 2022 | ($479.0K) | Aug 25, 2023 |
| FY2022 | May 31, 2021 | ($5.25M) | Aug 29, 2022 |
| FY2021 | May 31, 2020 | ($4.30M) | Oct 14, 2021 |
| FY2020 | May 31, 2019 | ($2.24M) | Aug 31, 2020 |
| FY2019 | May 31, 2018 | ($1.17M) | Aug 29, 2019 |
| FY2018 | May 31, 2017 | ($722.9K) | Aug 29, 2018 |
| FY2017 | May 31, 2016 | ($208.8K) | Aug 29, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2024 | $51.0K | Aug 29, 2025 |
| FY2024 | May 31, 2023 | $64.0K | Aug 28, 2024 |
| FY2023 | May 31, 2022 | $57.0K | Aug 25, 2023 |
| FY2022 | May 31, 2021 | $135.9K | Aug 29, 2022 |
| FY2021 | May 31, 2020 | $33.6K | Oct 14, 2021 |
| FY2020 | May 31, 2019 | $101.1K | Aug 31, 2020 |
| FY2019 | May 31, 2018 | $130.3K | Aug 29, 2019 |
| FY2018 | May 31, 2017 | $96.1K | Aug 29, 2018 |
| FY2017 | May 31, 2016 | $91.6K | Aug 29, 2017 |
| FY2016 | May 31, 2015 | $10.5K | Aug 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $5.95M | Aug 29, 2025 |
| FY2025 | May 31, 2024 | $9.25M | Aug 29, 2025 |
| FY2024 | May 31, 2023 | $14.45M | Aug 28, 2024 |
| FY2023 | May 31, 2022 | $11.37M | Aug 25, 2023 |
| FY2022 | May 31, 2021 | $11.82M | Aug 29, 2022 |
| FY2021 | May 31, 2020 | $17.26M | Oct 14, 2021 |
| FY2020 | May 31, 2019 | $5.25M | Aug 31, 2020 |
| FY2019 | May 31, 2018 | $5.22M | Aug 29, 2019 |
| FY2018 | May 31, 2017 | $5.02M | Aug 29, 2018 |
| FY2017 | May 31, 2016 | $5.73M | Aug 29, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $1.84M | Aug 29, 2025 |
| FY2025 | May 31, 2024 | $2.66M | Aug 29, 2025 |
| FY2024 | May 31, 2023 | $2.73M | Aug 28, 2024 |
| FY2023 | May 31, 2022 | $3.05M | Aug 25, 2023 |
| FY2022 | May 31, 2021 | $2.59M | Aug 29, 2022 |
| FY2021 | May 31, 2020 | $3.05M | Oct 14, 2021 |
| FY2020 | May 31, 2019 | $1.26M | Aug 31, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $4.11M | Aug 29, 2025 |
| FY2025 | May 31, 2024 | $6.59M | Aug 29, 2025 |
| FY2025 | May 31, 2023 | $11.72M | Aug 29, 2025 |
| FY2024 | May 31, 2022 | $8.33M | Aug 28, 2024 |
| FY2023 | May 31, 2021 | $9.23M | Aug 25, 2023 |
| FY2022 | May 31, 2020 | $14.21M | Aug 29, 2022 |
| FY2021 | May 31, 2019 | $3.98M | Oct 14, 2021 |
| FY2020 | May 31, 2018 | $4.33M | Aug 31, 2020 |
| FY2019 | May 31, 2017 | $4.49M | Aug 29, 2019 |
| FY2018 | May 31, 2016 | $5.22M | Aug 29, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | ($53.17M) | Aug 29, 2025 |
| FY2025 | May 31, 2024 | ($48.20M) | Aug 29, 2025 |
| FY2024 | May 31, 2023 | ($42.22M) | Aug 28, 2024 |
| FY2023 | May 31, 2022 | ($35.08M) | Aug 25, 2023 |
| FY2022 | May 31, 2021 | ($30.55M) | Aug 29, 2022 |
| FY2021 | May 31, 2020 | ($23.10M) | Oct 14, 2021 |
| FY2020 | May 31, 2019 | ($19.59M) | Aug 31, 2020 |
| FY2019 | May 31, 2018 | ($17.19M) | Aug 29, 2019 |
| FY2018 | May 31, 2017 | ($15.73M) | Aug 29, 2018 |
| FY2017 | May 31, 2016 | ($14.82M) | Aug 29, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | $2.40M | Aug 29, 2025 |
| FY2025 | May 31, 2024 | $4.17M | Aug 29, 2025 |
| FY2024 | May 31, 2023 | $9.72M | Aug 28, 2024 |
| FY2023 | May 31, 2022 | $5.92M | Aug 25, 2023 |
| FY2022 | May 31, 2021 | $4.20M | Aug 29, 2022 |
| FY2021 | May 31, 2020 | $8.64M | Oct 14, 2021 |
| FY2021 | May 31, 2019 | $686.8K | Oct 14, 2021 |
| FY2020 | May 31, 2018 | $1.20M | Aug 31, 2020 |
| FY2019 | May 31, 2017 | $1.23M | Aug 29, 2019 |
| FY2018 | May 31, 2016 | $1.89M | Aug 29, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | (2) | Aug 29, 2025 |
| FY2025 | May 31, 2024 | (2) | Aug 29, 2025 |
| FY2024 | May 31, 2023 | 0 | Aug 28, 2024 |
| FY2023 | May 31, 2022 | 0 | Aug 25, 2023 |
| FY2022 | May 31, 2021 | 0 | Aug 29, 2022 |
| FY2021 | May 31, 2020 | 0 | Oct 14, 2021 |
| FY2020 | May 31, 2019 | 0 | Aug 31, 2020 |
| FY2019 | May 31, 2018 | 0 | Aug 29, 2019 |
| FY2018 | May 31, 2017 | 0 | Aug 29, 2018 |
| FY2017 | May 31, 2016 | 0 | Aug 29, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | (2) | Aug 29, 2025 |
| FY2025 | May 31, 2024 | (2) | Aug 29, 2025 |
| FY2024 | May 31, 2023 | 0 | Aug 28, 2024 |
| FY2023 | May 31, 2022 | 0 | Aug 25, 2023 |
| FY2022 | May 31, 2021 | 0 | Aug 29, 2022 |
| FY2021 | May 31, 2020 | 0 | Oct 14, 2021 |
| FY2020 | May 31, 2019 | 0 | Aug 31, 2020 |
| FY2019 | May 31, 2018 | 0 | Aug 29, 2019 |
| FY2018 | May 31, 2017 | 0 | Aug 29, 2018 |
| FY2017 | May 31, 2016 | 0 | Aug 29, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | May 31, 2025 | 2.55M | Aug 29, 2025 |
| FY2025 | May 31, 2024 | 2.10M | Aug 29, 2025 |
| FY2024 | May 31, 2023 | 16.82M | Aug 28, 2024 |
| FY2023 | May 31, 2022 | 12.87M | Aug 25, 2023 |
| FY2022 | May 31, 2021 | 12.31M | Aug 29, 2022 |
| FY2021 | May 31, 2020 | 11.74M | Oct 14, 2021 |
| FY2020 | May 31, 2019 | 9.68M | Aug 31, 2020 |
| FY2019 | May 31, 2018 | 8.89M | Aug 29, 2019 |
| FY2018 | May 31, 2017 | 8.51M | Aug 29, 2018 |
| FY2017 | May 31, 2016 | 8.17M | Aug 29, 2017 |